Showing results (231-240 of 77,856) with videos related to

Sort By:
Pageof 7,786
Journal of Gastroenterology and Hepatology|September 22, 2005
Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virusChao-Hung Hung, Chuan-Mo Lee, Jing-Houng Wang, et al.
Hepatology International|March 5, 2021
Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessationYuan-Hung Kuo, Jing-Houng Wang, Chao-Hung Hung, et al.
European Journal of Gastroenterology & Hepatology|October 19, 2004
Correlation of quantitative assay of hepatitis B surface antigen and HBV DNA levels in asymptomatic hepatitis B virus carriersChien-Hung Chen, Chuan-Mo Lee, Jing-Houng Wang, et al.
Journal of Clinical Microbiology|March 31, 2012
Is hepatitis C virus core antigen an adequate marker for community screening?Yuan-Hung Kuo, Kuo-Chin Chang, Jing-Houng Wang, et al.
Case Reports in Oncology|July 16, 2021
Hepatic Clostridium Perfringens Abscess Formation after Radiofrequency Ablation Therapy for Hepatocellular Carcinoma: Report of a Rare CaseMing-Hung Wang, Yuan-Hung Kuo, Yi-Hao Yen, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 14, 2008
History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patientsSteven M Brunelli, Marshall M Joffe, Rubeen K Israni, et al.
Kidney International|August 19, 2020
Outcomes of patients with end-stage kidney disease hospitalized with COVID-19Jia H Ng, Jamie S Hirsch, Rimda Wanchoo, et al.
Medicine|February 7, 2020
Laser acupuncture for refractory coccydynia after traumatic coccyx fracture: A case reportChien-Hung Lin, Szu-Ying Wu, Wen-Long Hu, et al.
American Journal of Nephrology|November 28, 2014
Increasing hip fractures in patients receiving hemodialysis and peritoneal dialysisAnna T Mathew, Azzour Hazzan, Kenar D Jhaveri, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 4, 2014
A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5Geoffrey A Block, Steven Fishbane, Mariano Rodriguez, et al.
Pageof 7,786